Frontiers in Immunology ( IF 5.7 ) Pub Date : 2020-05-15 , DOI: 10.3389/fimmu.2020.01215 Valentina Bianchi 1, 2 , Alexandre Harari 1, 2 , George Coukos 1
Mutation-derived neoantigens are taking central stage as a determinant in eliciting effective antitumor immune responses following adoptive T-cell therapies. These mutations are patient-specific, and their targeting calls for highly personalized pipelines. The promising clinical outcomes of tumor-infiltrating lymphocyte (TIL) therapy have spurred interest in generating T-cell infusion products that have been selectively enriched in neoantigen (or autologous tumor) reactivity. The implementation of an isolation step, prior to T-cell
中文翻译:
癌症的新抗原特异性过继细胞疗法:使T细胞产品更具个性化。
在过继T细胞疗法后,突变衍生的新抗原在引发有效的抗肿瘤免疫反应中起着决定性作用。这些突变是特定于患者的,其靶向性要求高度个性化的流程。肿瘤浸润淋巴细胞(TIL)治疗的有希望的临床结果激发了人们对产生T细胞输注产品的兴趣,该产品已选择性地富集了新抗原(或自体肿瘤)反应性。在T单元之前执行隔离步骤